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Dr. Russell raises important points regarding the diagnostic
criteria for chronic migraine (CM) and medication overuse
headache (MOH). We agree that the definitions for these
entities have posed challenges for the past two decades.
The ICHD-2 diagnostic criteria for CM and MOH were
evolving as the PREEMPT clinical trial program was
developed and launched. In the original ICHD-2 definition
of MOH, remission of headache [15 days per month fol-
lowing discontinuation of medication was required. As a
consequence, the diagnosis could be assigned only to
individuals who no longer had the condition. The ICHD-2R
definition of MOH no longer requires remission after
withdrawal [1]. A history of headache escalation during a
period of medication overuse is still required by ICHD-2R,
though in the vast majority of patients it is not possible to
reliably determine if medication overuse is a cause or a
consequence of increasing headache frequency. Moreover,
contrary to conventional wisdom, there is no evidence from
controlled trials that the withdrawal of acute medications
alone, in those who ‘‘overuse’’ them, leads to the long-term
remission of headache.
In the PREEMPT program, patients who otherwise met
study criteria for CM were not excluded if they were
making frequent use of acute medication. Contrary to
Dr. Russell’s assertion, additional data are needed to
determine which of these patients meet criteria for MOH.
The decision not to exclude patients overusing acute
medication was made based on consultation with members
of the Task Force of the International Headache Society
Clinical Trials Subcommittee, and is consistent with their
published guidelines for controlled trials of prophylactic
treatment of CM in adults [2]. These guidelines reflect the
high prevalence of medication overuse in CM patients, and
recommend the inclusion and stratification of these patients
in clinical studies. In line with these guidelines, patients
with medication overuse were stratified at randomization in
the PREEMPT clinical program [3]. If patients with med-
ication overuse are excluded, we lose the opportunity to
address the benefits of treatment in a large group with
disabling headache and an unmet treatment need. Results
from an independent clinic-based study designed to assess
the overlap between ICHD-2R and other proposed diag-
nostic criteria for CM (including PREEMPT enrollment
criteria) determined that there was significant overlap
between these definitions [4].
We completely agree with Dr. Russell that subgroup
analyses are warranted. Data have been presented on the
medication overuse subpopulation demonstrating efficacy
of onabotulinumtoxinA compared to placebo on multiple
headache symptom measures [5], and a manuscript is in
progress. Additional post hoc analysis of subgroup popu-
lations, such as those PREEMPT patients who have taken
prior prophylaxis, are currently underway and will also be
detailed in future publications.
We believe the PREEMPT study enrolled patients rep-
resentative of the CM population and that the results of the
program have greater generalizability because of our
inclusion criteria. These studies show that onabotulinum-
toxinA treatment compared to placebo resulted in clinically
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meaningful outcomes; significantly reduced headache fre-
quency; and significantly improved functioning, vitality,
and overall quality of life [3]. As clinicians dedicated to the
care of patients with headache, identification and success-
ful prophylactic treatment of this highly disabled patient





On behalf of the PREEMPT Chronic Migraine Study
Group
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution and reproduction in any medium, provided the original
author(s) and source are credited.
References
1. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby
PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F,
Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix
criteria open for a broader concept of chronic migraine. Cepha-
lalgia 26:742–746
2. Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton
RB, Pascual J, Wang SJ (2008) Guidelines for controlled trials of
prophylactic treatment of chronic migraine in adults. Cephalalgia
28:484–495
3. Dodick DW, Turkel CC, Degryse RE, Aurora SK, Silberstein SD,
Lipton RB, Diener HC, Brin MF, on behalf of the PREEMPT
Chronic Migraine Study Group (2010) OnabotulinumtoxinA for
treatment of chronic migraine: pooled results from the double-
blind, randomized, placebo-controlled phases of the PREEMPT
clinical program. Headache 50:921–963
4. Bigal M, Rapoport A, Sheftell F, Tepper S, Lipton R (2007) The
International Classification of Headache Disorders revised criteria
for chronic migraine-field testing in a headache specialty clinic.
Cephalalgia 27:230–234
5. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Sirimanne
M, Degryse RE, Turkel CC (2009) OnabotulinumtoxinA for
treatment of chronic migraine: analysis of the PREEMPT chronic
migraine subgroup who were overusing acute headache medica-
tions at baseline. In: 14th international headache congress,
Philadelphia, PA, September 2009
138 J Headache Pain (2011) 12:137–138
123
